WOBURN, Mass. & TOKYO--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 ...

Cancer-drug developer ArQule spiked as much as 102% in early Monday trading after Merck said it would acquire the firm in a $2.7 billion takeover. Merck offered $20 per share in the all-cash bid, more ...

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the company’s AKT inhibitor, ARQ 751, in two poster presentations at the 2019 ...

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq:ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Now what: ...

ArQule (ARQL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most ...

WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NAS: ARQL) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 087, an orally bioavailable, potent multi-kinase ...

If you’re interested in ArQule, Inc. (NASDAQ:ARQL), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio.

Merck liked what it saw with ArQule's promising pipeline candidate ARQ 531. The experimental drug is currently in a phase 2 clinical study targeting the treatment of B-cell malignancies. Merck ...

Shares of ArQule (NASDAQ: ARQL) rose over 70% today after the company reported full-year 2018 operating results and provided full-year 2019 guidance. That said, investors are probably used to wild ...